Plasma Cell Myeloma
Conditions
Brief summary
This phase I/II trial studies the side effects and best dose of melphalan hydrochloride in treating participants with newly-diagnosed multiple myeloma who are undergoing a donor stem cell transplantation. Giving chemotherapy before a donor stem cell transplantation helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the participant, they may help the participant's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving melphalan hydrochloride before a donor stem cell transplantation may work better than standard chemotherapy in helping to prevent multiple myeloma from coming back.
Detailed description
PRIMARY OBJECTIVES: I. To determine the optimal dose and schedule of melphalan for injection (melphalan hydrochloride \[Evomela\]) prior to autologous hematopoietic stem cell transplantation (auto-HCT) for multiple myeloma (MM). II. To collect the pharmacokinetic data and compare the exposure-response evaluations between the 2 infusion schedules. SECONDARY OBJECTIVES: I. To determine the incidence of treatment related mortality (TRM) at day 90 after auto-HCT in newly diagnosed myeloma patients treated on different schedules and doses of Evomela. II. To determine the rate of minimal residual disease (MRD) negative complete response (CR) rate at day 90 after auto-HCT in newly diagnosed myeloma patients treated on different schedules and doses of Evomela. III. To determine the progression-free survival (PFS) after auto-HCT in newly diagnosed myeloma patients treated on different schedules and doses of Evomela. OUTLINE: This is a phase I, dose escalation study of melphalan hydrochloride followed by a phase II study. PREPARATIVE REGIMEN: Participants are randomized to 1 of 2 groups. GROUP 1: Participants receive melphalan hydrochloride intravenously (IV) over 30-60 minutes on day -2. GROUP 2: Participants receive melphalan hydrochloride IV over 8-9 hours on day -2. TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes. POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz subcutaneously (SC) once daily (QD) starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an absolute neutrophil count (ANC) of 0.5 x 10\^9/L. After completion of study treatment, participants are followed up at 3 months, every 3 months for 1 year, and then annually for 1 year.
Interventions
PROCEDUREAutologous Hematopoietic Stem Cell Transplantation
Undergo HSCT
BIOLOGICALFilgrastim-sndz
Given SC
Given IV
Sponsors
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients with non-relapsed multiple myeloma in complete response (CR), partial remission (PR), very good partial remission (VGPR), or symptomatic stable disease (no evidence of progression) including patients with light chain multiple myeloma (MM) detected in the serum by free light chain assay OR * Patients with non-secretory multiple myeloma (absence of a monoclonal protein \[M protein\] in serum as measured by electrophoresis \[serum protein electrophoresis (SPEP)\] and immunofixation (serum immunofixation electrophoresis \[SIFE\]) and the absence of Bence Jones protein in the urine \[urine protein electrophoresis (UPEP)\] defined by use of conventional electrophoresis and immunofixation \[urine immunofixation electrophoresis (UIFE) techniques\]) but with measurable disease on imaging studies like magnetic resonance imaging (MRI), computed tomography (CT) scan or positron emission tomography (PET) scan. * Patients who have received at least two cycles of initial systemic therapy and are within 2 to 12 months of the first dose. Mobilization therapy is not considered initial therapy. * Karnofsky performance score 70% or higher. * Left ventricular ejection fraction at rest \> 40% within 3 months of registration. * Bilirubin \< 2 x the upper limit of normal (except patients with Gilbert syndrome in whom bilirubin level of \> 2 x upper normal limit will be allowed) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x the upper limit of normal. * Creatinine clearance of \>= 40 mL/min, estimated or calculated using the Cockcroft-Gault equation. * Pulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), forced vital capacity (FVC) \> 50% of predicted value (corrected for hemoglobin) within 3 months of registration. * All female and male subjects of reproductive potential must consent to the use of effective contraceptive methods as advised by the study doctor during treatment. * Signed informed consent form.
Exclusion criteria
* Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and progression of clinical symptoms). * Patients seropositive for the human immunodeficiency virus (HIV). * Patients with history of myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. * Patients participating in an investigational new drug protocol within 14 days before enrollment. * Female patients who are pregnant (positive beta-human chorionic gonadotropin \[b-HCG\]) or breast feeding. * Prior hematopoietic cell transplantation allogeneic or autologous (A prior autologous HCT will be allowed as long as it was part of tandem transplantation). * Prior organ transplant requiring immunosuppressive therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Optimal Dose and Schedule of Evomela Prior to Autologous Transplant. | Within 30 days after the start of infusion | Dose limiting toxicity will be defined as grade 4 mucositis or any grade 4 or 5 non-hematologic or non-infectious toxicity occurring within 30 days from the start of infusion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | From the date of Evomela injection up to 1 year | Number of participants that are still alive and disease free one year post autologous transplant. |
| Treatment Related Mortality (TRM). | At day 90 post-transplant | Number of participants expired from non-disease relapse within 90 days post transplant |
| Number of Participants That Have Achieved Complete Response (CR). | At 90 days post-transplant | Number of participants that have achieved Complete response (CR). Complete response definition is negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow aspirates. |
Countries
United States
Participant flow
Recruitment details
All participants were registered in MD Anderson Cancer Center.
Participants by arm
| Arm | Count |
|---|---|
| Group1_Dose 1 200mgm2 PREPARATIVE REGIMEN: Participants receive melphalan IV over 30-60 minutes on day -2.
TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.
POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\^9/L.
Autologous Hematopoietic Stem Cell Transplantation: Undergo HSCT
Filgrastim-sndz: Given SC
Melphalan Hydrochloride: Given IV | 4 |
| Group 1_Dose 2 225mgm2 PREPARATIVE REGIMEN: Participants receive melphalan IV over 30-60 minutes on day -2.
TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.
POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\^9/L.
Autologous Hematopoietic Stem Cell Transplantation: Undergo HSCT
Filgrastim-sndz: Given SC
Melphalan Hydrochloride: Given IV | 27 |
| Group 2_Dose 1 200mgm2 PREPARATIVE REGIMEN: Participants receive melphalan IV over 8-9 hours on day -2.
TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.
POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\^9/L.
Autologous Hematopoietic Stem Cell Transplantation: Undergo HSCT
Filgrastim-sndz: Given SC
Melphalan Hydrochloride: Given IV | 4 |
| Group 2_Dose 225mgm2 PREPARATIVE REGIMEN: Participants receive melphalan IV over 8-9 hours on day -2.
TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.
POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\^9/L.
Autologous Hematopoietic Stem Cell Transplantation: Undergo HSCT
Filgrastim-sndz: Given SC
Melphalan Hydrochloride: Given IV | 27 |
| Total | 62 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Disease Progression | 0 | 0 | 1 | 0 |
| Overall Study | Inadequate supply on study drug | 1 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Group1_Dose 1 200mgm2 | Group 1_Dose 2 225mgm2 | Group 2_Dose 1 200mgm2 | Group 2_Dose 225mgm2 | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 8 Participants | 0 Participants | 5 Participants | 15 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants | 19 Participants | 4 Participants | 22 Participants | 47 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 3 Participants | 1 Participants | 4 Participants | 9 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 24 Participants | 3 Participants | 23 Participants | 53 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment United States | 4 participants | 27 participants | 4 participants | 27 participants | 62 participants |
| Sex: Female, Male Female | 1 Participants | 12 Participants | 2 Participants | 5 Participants | 20 Participants |
| Sex: Female, Male Male | 3 Participants | 15 Participants | 2 Participants | 22 Participants | 42 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 4 | 0 / 27 | 0 / 4 | 0 / 27 |
| other Total, other adverse events | 3 / 4 | 27 / 27 | 4 / 4 | 27 / 27 |
| serious Total, serious adverse events | 0 / 4 | 0 / 27 | 0 / 4 | 0 / 27 |
Outcome results
Primary
Optimal Dose and Schedule of Evomela Prior to Autologous Transplant.
Dose limiting toxicity will be defined as grade 4 mucositis or any grade 4 or 5 non-hematologic or non-infectious toxicity occurring within 30 days from the start of infusion.
Time frame: Within 30 days after the start of infusion
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group1_Dose 1 200mgm2 | Optimal Dose and Schedule of Evomela Prior to Autologous Transplant. | Grade 4 Mucositis | 0 Participants |
| Group1_Dose 1 200mgm2 | Optimal Dose and Schedule of Evomela Prior to Autologous Transplant. | Grade 4 non-hematologic or non-infectious toxicity | 0 Participants |
| Group 1_Dose 2 225mgm2 | Optimal Dose and Schedule of Evomela Prior to Autologous Transplant. | Grade 4 non-hematologic or non-infectious toxicity | 0 Participants |
| Group 1_Dose 2 225mgm2 | Optimal Dose and Schedule of Evomela Prior to Autologous Transplant. | Grade 4 Mucositis | 0 Participants |
| Group 2_Dose 1 200mgm2 | Optimal Dose and Schedule of Evomela Prior to Autologous Transplant. | Grade 4 Mucositis | 0 Participants |
| Group 2_Dose 1 200mgm2 | Optimal Dose and Schedule of Evomela Prior to Autologous Transplant. | Grade 4 non-hematologic or non-infectious toxicity | 0 Participants |
| Group 2_Dose 225mgm2 | Optimal Dose and Schedule of Evomela Prior to Autologous Transplant. | Grade 4 non-hematologic or non-infectious toxicity | 0 Participants |
| Group 2_Dose 225mgm2 | Optimal Dose and Schedule of Evomela Prior to Autologous Transplant. | Grade 4 Mucositis | 0 Participants |
Secondary
Number of Participants That Have Achieved Complete Response (CR).
Number of participants that have achieved Complete response (CR). Complete response definition is negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow aspirates.
Time frame: At 90 days post-transplant
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group1_Dose 1 200mgm2 | Number of Participants That Have Achieved Complete Response (CR). | 1 Participants |
| Group 1_Dose 2 225mgm2 | Number of Participants That Have Achieved Complete Response (CR). | 13 Participants |
| Group 2_Dose 1 200mgm2 | Number of Participants That Have Achieved Complete Response (CR). | 2 Participants |
| Group 2_Dose 225mgm2 | Number of Participants That Have Achieved Complete Response (CR). | 13 Participants |
Secondary
Progression-free Survival (PFS)
Number of participants that are still alive and disease free one year post autologous transplant.
Time frame: From the date of Evomela injection up to 1 year
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group1_Dose 1 200mgm2 | Progression-free Survival (PFS) | 2 Participants |
| Group 1_Dose 2 225mgm2 | Progression-free Survival (PFS) | 21 Participants |
| Group 2_Dose 1 200mgm2 | Progression-free Survival (PFS) | 2 Participants |
| Group 2_Dose 225mgm2 | Progression-free Survival (PFS) | 21 Participants |
Secondary
Treatment Related Mortality (TRM).
Number of participants expired from non-disease relapse within 90 days post transplant
Time frame: At day 90 post-transplant
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group1_Dose 1 200mgm2 | Treatment Related Mortality (TRM). | 0 Participants |
| Group 1_Dose 2 225mgm2 | Treatment Related Mortality (TRM). | 0 Participants |
| Group 2_Dose 1 200mgm2 | Treatment Related Mortality (TRM). | 0 Participants |
| Group 2_Dose 225mgm2 | Treatment Related Mortality (TRM). | 0 Participants |